메뉴 건너뛰기




Volumn 12, Issue 7, 2014, Pages 783-791

A cure for HIV: Is it in sight?

Author keywords

Cure; Functional; HIV; Kick and kill; Sterilising

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CYTOMEGALOVIRUS VACCINE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 7; VORINOSTAT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

EID: 84902472796     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.910112     Document Type: Review
Times cited : (25)

References (62)
  • 2
    • 0028792184 scopus 로고
    • In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency
    • Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995;1:1284-90
    • (1995) Nat Med , vol.1 , pp. 1284-1290
    • Chun, T.W.1    Finzi, D.2    Margolick, J.3
  • 3
    • 14444273439 scopus 로고    scopus 로고
    • Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
    • Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300
    • (1997) Science , vol.278 , pp. 1295-1300
    • Finzi, D.1    Hermankova, M.2    Pierson, T.3
  • 4
    • 78549235738 scopus 로고    scopus 로고
    • Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: Implications for eradication
    • Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010;24: 2803-8
    • (2010) AIDS , vol.24 , pp. 2803-2808
    • Chun, T.W.1    Justement, J.S.2    Murray, D.3
  • 5
    • 53849134844 scopus 로고    scopus 로고
    • Cellular reservoirs of HIV-1 and their role in viral persistence
    • Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008;6:388-400
    • (2008) Curr HIV Res , vol.6 , pp. 388-400
    • Alexaki, A.1    Liu, Y.2    Wigdahl, B.3
  • 6
    • 77950531446 scopus 로고    scopus 로고
    • HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs
    • Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010;16:446-51
    • (2010) Nat Med , vol.16 , pp. 446-451
    • Carter, C.C.1    Onafuwa-Nuga, A.2    McNamara, L.A.3
  • 7
    • 60549090253 scopus 로고    scopus 로고
    • Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation
    • Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360: 692-8
    • (2009) N Engl J Med , vol.360 , pp. 692-698
    • Hutter, G.1    Nowak, D.2    Mossner, M.3
  • 8
    • 84878503062 scopus 로고    scopus 로고
    • Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient
    • Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013;9:e1003347
    • (2013) PLoS Pathog , vol.9
    • Yukl, S.A.1    Boritz, E.2    Busch, M.3
  • 9
    • 84877278315 scopus 로고    scopus 로고
    • Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation
    • Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013;207: 1694-702
    • (2013) J Infect Dis , vol.207 , pp. 1694-1702
    • Henrich, T.J.1    Hu, Z.2    Li, J.Z.3
  • 11
    • 84895487305 scopus 로고    scopus 로고
    • Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV
    • Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014;370:901-10
    • (2014) N Engl J Med , vol.370 , pp. 901-910
    • Tebas, P.1    Stein, D.2    Tang, W.W.3
  • 12
    • 78650735673 scopus 로고    scopus 로고
    • Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo
    • Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010;28:839-47
    • (2010) Nat Biotechnol , vol.28 , pp. 839-847
    • Holt, N.1    Wang, J.2    Kim, K.3
  • 13
    • 84873734105 scopus 로고    scopus 로고
    • RNA-guided human genome engineering via Cas9
    • Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science 2013;339:823-6
    • (2013) Science , vol.339 , pp. 823-826
    • Mali, P.1    Yang, L.2    Esvelt, K.M.3
  • 14
    • 84883305437 scopus 로고    scopus 로고
    • Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
    • Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013;3:2510
    • (2013) Sci Rep , vol.3 , pp. 2510
    • Ebina, H.1    Misawa, N.2    Kanemura, Y.3    Koyanagi, Y.4
  • 15
    • 84878459431 scopus 로고    scopus 로고
    • Reactivation of latent HIV by histone deacetylase inhibitors
    • Shirakawa K, Chavez L, Hakre S, et al. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 2013;21:277-85
    • (2013) Trends Microbiol , vol.21 , pp. 277-285
    • Shirakawa, K.1    Chavez, L.2    Hakre, S.3
  • 16
    • 84864203255 scopus 로고    scopus 로고
    • Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
    • Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487:482-5
    • (2012) Nature , vol.487 , pp. 482-485
    • Archin, N.M.1    Liberty, A.L.2    Kashuba, A.D.3
  • 17
    • 84863337769 scopus 로고    scopus 로고
    • Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation
    • Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012;36:491-501
    • (2012) Immunity , vol.36 , pp. 491-501
    • Shan, L.1    Deng, K.2    Shroff, N.S.3
  • 18
    • 84878981012 scopus 로고    scopus 로고
    • Barriers to a cure for HIV: New ways to target and eradicate HIV-1 reservoirs
    • Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013;381:2109-17
    • (2013) Lancet , vol.381 , pp. 2109-2117
    • Katlama, C.1    Deeks, S.G.2    Autran, B.3
  • 19
    • 13744259064 scopus 로고    scopus 로고
    • IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART
    • Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005;115:128-37
    • (2005) J Clin Invest , vol.115 , pp. 128-137
    • Wang, F.X.1    Xu, Y.2    Sullivan, J.3
  • 20
    • 84879302206 scopus 로고    scopus 로고
    • Interleukin-7 promotes HIV persistence during antiretroviral therapy
    • Vandergeeten C, Fromentin R, DaFonseca S, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013;121:4321-9
    • (2013) Blood , vol.121 , pp. 4321-4329
    • Vandergeeten, C.1    Fromentin, R.2    Dafonseca, S.3
  • 21
    • 77954685640 scopus 로고    scopus 로고
    • Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs
    • Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog 2010;6:e1000803
    • (2010) PLoS Pathog , vol.6
    • Berger, E.A.1    Pastan, I.2
  • 23
    • 79955468799 scopus 로고    scopus 로고
    • Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control
    • Hersperger AR, Migueles SA, Betts MR, Connors M. Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr Opin HIV AIDS 2011;6:169-73
    • (2011) Curr Opin HIV AIDS , vol.6 , pp. 169-173
    • Hersperger, A.R.1    Migueles, S.A.2    Betts, M.R.3    Connors, M.4
  • 24
    • 79952072932 scopus 로고    scopus 로고
    • Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART
    • Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 2011;7:e1001300
    • (2011) PLoS Pathog , vol.7
    • Graf, E.H.1    Mexas, A.M.2    Yu, J.J.3
  • 25
    • 84881319698 scopus 로고    scopus 로고
    • Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance
    • Graf EH, Pace MJ, Peterson BA, et al. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance. PLoS One 2013;8: e71879
    • (2013) PLoS One , vol.8
    • Graf, E.H.1    Pace, M.J.2    Peterson, B.A.3
  • 26
    • 84885669019 scopus 로고    scopus 로고
    • Immune clearance of highly pathogenic SIV infection
    • Hansen SG, Piatak M Jr, Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013;502:100-4
    • (2013) Nature , vol.502 , pp. 100-104
    • Hansen, S.G.1    Piatak Jr., M.2    Ventura, A.B.3
  • 27
    • 84877949177 scopus 로고    scopus 로고
    • Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire
    • Casazza JP, Bowman KA, Adzaku S, et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis 2013;207:1829-40
    • (2013) J Infect Dis , vol.207 , pp. 1829-1840
    • Casazza, J.P.1    Bowman, K.A.2    Adzaku, S.3
  • 28
    • 84872037286 scopus 로고    scopus 로고
    • A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication
    • Garcia F, Climent N, Guardo AC, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med 2013;5:166ra162
    • (2013) Sci Transl Med , vol.5
    • Garcia, F.1    Climent, N.2    Guardo, A.C.3
  • 29
    • 32544459770 scopus 로고    scopus 로고
    • Restoring function in exhausted CD8 T cells during chronic viral infection
    • Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-7
    • (2006) Nature , vol.439 , pp. 682-687
    • Barber, D.L.1    Wherry, E.J.2    Masopust, D.3
  • 30
    • 62249172189 scopus 로고    scopus 로고
    • Enhancing SIV-specific immunity in vivo by PD-1 blockade
    • Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009;458:206-10
    • (2009) Nature , vol.458 , pp. 206-210
    • Velu, V.1    Titanji, K.2    Zhu, B.3
  • 31
    • 84873738644 scopus 로고    scopus 로고
    • Attacking the HIV reservoir from the immune and viral perspective
    • Massanella M, Martinez-Picado J, Blanco J. Attacking the HIV reservoir from the immune and viral perspective. Curr HIV/AIDS Rep 2013;10:33-41
    • (2013) Curr HIV/AIDS Rep , vol.10 , pp. 33-41
    • Massanella, M.1    Martinez-Picado, J.2    Blanco, J.3
  • 32
    • 84879759020 scopus 로고    scopus 로고
    • Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
    • Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44
    • (2013) N Engl J Med , vol.369 , pp. 134-144
    • Hamid, O.1    Robert, C.2    Daud, A.3
  • 33
    • 82555187124 scopus 로고    scopus 로고
    • Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication
    • Pallikkuth S, Rogers K, Villinger F, et al. Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication. Vaccine 2011;29:9229-38
    • (2011) Vaccine , vol.29 , pp. 9229-9238
    • Pallikkuth, S.1    Rogers, K.2    Villinger, F.3
  • 34
    • 84862889768 scopus 로고    scopus 로고
    • Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes
    • Casucci M, Bondanza A. Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes. J Cancer 2011;2:378-82
    • (2011) J Cancer , vol.2 , pp. 378-382
    • Casucci, M.1    Bondanza, A.2
  • 35
    • 84860718270 scopus 로고    scopus 로고
    • Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells
    • Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012;4:132ra153
    • (2012) Sci Transl Med , vol.4
    • Scholler, J.1    Brady, T.L.2    Binder-Scholl, G.3
  • 36
    • 84887028999 scopus 로고    scopus 로고
    • Absence of detectable HIV-1 viremia after treatment cessation in an infant
    • Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369:1828-35
    • (2013) N Engl J Med , vol.369 , pp. 1828-1835
    • Persaud, D.1    Gay, H.2    Ziemniak, C.3
  • 37
    • 84865717158 scopus 로고    scopus 로고
    • HIV-1 control after transient antiretroviral treatment initiated in primary infection: Role of patient characteristics and effect of therapy
    • Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 2012;17:1001-9
    • (2012) Antivir Ther , vol.17 , pp. 1001-1009
    • Goujard, C.1    Girault, I.2    Rouzioux, C.3
  • 38
    • 84875985311 scopus 로고    scopus 로고
    • Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study
    • Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013;9:e1003211
    • (2013) PLoS Pathog , vol.9
    • Saez-Cirion, A.1    Bacchus, C.2    Hocqueloux, L.3
  • 39
    • 84872452352 scopus 로고    scopus 로고
    • Short-course antiretroviral therapy in primary HIV infection
    • Investigators ST
    • Investigators ST, Fidler S, Porter K, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368:207-17
    • (2013) N Engl J Med , vol.368 , pp. 207-217
    • Fidler, S.1    Porter, K.2
  • 40
    • 84886401909 scopus 로고    scopus 로고
    • Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
    • Stohr W, Fidler S, McClure M, et al. Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS ONE 2013;8:e78287
    • (2013) PLoS ONE , vol.8
    • Stohr, W.1    Fidler, S.2    McClure, M.3
  • 41
    • 20244376915 scopus 로고    scopus 로고
    • Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1
    • Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005;191: 1410-18
    • (2005) J Infect Dis , vol.191 , pp. 1410-1418
    • Strain, M.C.1    Little, S.J.2    Daar, E.S.3
  • 42
    • 84885058930 scopus 로고    scopus 로고
    • Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size
    • Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013;208: 1202-11
    • (2013) J Infect Dis , vol.208 , pp. 1202-1211
    • Jain, V.1    Hartogensis, W.2    Bacchetti, P.3
  • 43
    • 0034724371 scopus 로고    scopus 로고
    • Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes
    • Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000;97:3382-7
    • (2000) Proc Natl Acad Sci USA , vol.97 , pp. 3382-3387
    • Oxenius, A.1    Price, D.A.2    Easterbrook, P.J.3
  • 44
    • 84873472629 scopus 로고    scopus 로고
    • Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies
    • Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013;9:e1003174
    • (2013) PLoS Pathog , vol.9
    • Eriksson, S.1    Graf, E.H.2    Dahl, V.3
  • 45
    • 84878482232 scopus 로고    scopus 로고
    • Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay
    • Laird GM, Eisele EE, Rabi SA, et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 2013;9:e1003398
    • (2013) PLoS Pathog , vol.9
    • Laird, G.M.1    Eisele, E.E.2    Rabi, S.A.3
  • 46
    • 84873421734 scopus 로고    scopus 로고
    • Quantitation of integrated proviral DNA in viral reservoirs
    • Graf EH, O'Doherty U. Quantitation of integrated proviral DNA in viral reservoirs. Curr Opin HIV AIDS 2013;8:100-5
    • (2013) Curr Opin HIV AIDS , vol.8 , pp. 100-105
    • Graf, E.H.1    O'doherty, U.2
  • 47
    • 84886769508 scopus 로고    scopus 로고
    • Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure
    • Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013;155: 540-51
    • (2013) Cell , vol.155 , pp. 540-551
    • Ho, Y.C.1    Shan, L.2    Hosmane, N.N.3
  • 48
    • 84871797372 scopus 로고    scopus 로고
    • Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration
    • Azzoni L, Foulkes AS, Papasavvas E, et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 2013;207:213-22
    • (2013) J Infect Dis , vol.207 , pp. 213-222
    • Azzoni, L.1    Foulkes, A.S.2    Papasavvas, E.3
  • 49
    • 33751515147 scopus 로고    scopus 로고
    • Strategies for Management of Antiretroviral Therapy Study G. CD4+ count-guided interruption of antiretroviral treatment
    • El-Sadr WM, Lundgren J, Neaton JD, Gordin F, et al. Strategies for Management of Antiretroviral Therapy Study G. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355: 2283-96
    • (2006) N Engl J Med , vol.355 , pp. 2283-2296
    • El-Sadr, W.M.1    Lundgren, J.2    Neaton, J.D.3    Gordin, F.4
  • 50
    • 34548222243 scopus 로고    scopus 로고
    • Risk of cancers during interrupted antiretroviral therapy in the SMART study
    • Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007;21:1957-63
    • (2007) AIDS , vol.21 , pp. 1957-1963
    • Silverberg, M.J.1    Neuhaus, J.2    Bower, M.3
  • 51
    • 84888005650 scopus 로고    scopus 로고
    • HIV-1 coreceptor switch during 2 years of structured treatment interruptions
    • Baroncelli S, Galluzzo CM, Andreotti M, et al. HIV-1 coreceptor switch during 2 years of structured treatment interruptions. Eur J Clin Microbiol Infect Dis 2013;32:1565-70
    • (2013) Eur J Clin Microbiol Infect Dis , vol.32 , pp. 1565-1570
    • Baroncelli, S.1    Galluzzo, C.M.2    Andreotti, M.3
  • 52
    • 67649666969 scopus 로고    scopus 로고
    • CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART
    • Maggiolo F, Airoldi M, Callegaro A, et al. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS 2009;23:799-807
    • (2009) AIDS , vol.23 , pp. 799-807
    • Maggiolo, F.1    Airoldi, M.2    Callegaro, A.3
  • 53
    • 33745102005 scopus 로고    scopus 로고
    • A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/-interleukin 2: Results of ACTG A5102
    • Henry K, Katzenstein D, Cherng DW, et al. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/-interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr 2006;42:140-8
    • (2006) J Acquir Immune Defic Syndr , vol.42 , pp. 140-148
    • Henry, K.1    Katzenstein, D.2    Cherng, D.W.3
  • 54
    • 33746479812 scopus 로고    scopus 로고
    • CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the Staccato randomised trial
    • Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006;368:459-65
    • (2006) Lancet , vol.368 , pp. 459-465
    • Ananworanich, J.1    Gayet-Ageron, A.2    Le Braz, M.3
  • 55
    • 0037324326 scopus 로고    scopus 로고
    • Enhanced risk of HIV sexual transmission during structured treatment interruption
    • Teicher E, Casagrande T, Vittecoq D. Enhanced risk of HIV sexual transmission during structured treatment interruption. Sex Transm Infect 2003;79:74
    • (2003) Sex Transm Infect , vol.79 , pp. 74
    • Teicher, E.1    Casagrande, T.2    Vittecoq, D.3
  • 56
    • 55949084601 scopus 로고    scopus 로고
    • Inflammatory and coagulation biomarkers and mortality in patients with HIV infection
    • Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203
    • (2008) PLoS Med , vol.5
    • Kuller, L.H.1    Tracy, R.2    Belloso, W.3
  • 57
    • 79952335046 scopus 로고    scopus 로고
    • Plasma levels of soluble CD14 independently predict mortality in HIV infection
    • Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203: 780-90
    • (2011) J Infect Dis , vol.203 , pp. 780-790
    • Sandler, N.G.1    Wand, H.2    Roque, A.3
  • 58
    • 70349434886 scopus 로고    scopus 로고
    • Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection
    • Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009;200: 973-83
    • (2009) J Infect Dis , vol.200 , pp. 973-983
    • Rodger, A.J.1    Fox, Z.2    Lundgren, J.D.3
  • 59
    • 67049172548 scopus 로고    scopus 로고
    • HIV increases markers of cardiovascular risk: Results from a randomized, treatment interruption trial
    • Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009;23:929-39
    • (2009) AIDS , vol.23 , pp. 929-939
    • Calmy, A.1    Gayet-Ageron, A.2    Montecucco, F.3
  • 60
    • 79952116429 scopus 로고    scopus 로고
    • A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir
    • Piketty C, Weiss L, Assoumou L, et al. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J Med Virol 2010;82:1819-28
    • (2010) J Med Virol , vol.82 , pp. 1819-1828
    • Piketty, C.1    Weiss, L.2    Assoumou, L.3
  • 61
    • 84866735012 scopus 로고    scopus 로고
    • Continuous versus intermittent treatment strategies during primary HIV-1 infection: The randomized ANRS INTERPRIM Trial
    • Goujard C, Emilie D, Roussillon C, et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial. AIDS 2012;26:1895-905
    • (2012) AIDS , vol.26 , pp. 1895-1905
    • Goujard, C.1    Emilie, D.2    Roussillon, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.